News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nexvet Revered at Informa Life Sciences Conference in London



5/16/2013 9:37:56 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

(16 May 2013) Melbourne, Australia. Australian veterinary biologic drug developer Nexvet Biopharma (Nexvet) presented at the Informa Life Sciences Conference for Research and Development in Veterinary Medicine on Wednesday 15 May in London, UK.

The Informa Life Sciences Conference is the leading international veterinary conference focused on the commercial aspects of animal research and development. The Conference engages leading researchers and clinicians in the areas of veterinary medicine, to deliver presentations on market trends, R&D challenges, veterinary medicine formulation strategies and diagnostics.

Nexvet’s presentation was delivered by the Company’s Chief Scientific Officer, and inventor of its core technology, Professor David Gearing. He detailed the functionality of Nexvet’s PETisationTM technology, its advantages over existing therapies, and how it is overcoming barriers to entry in the veterinary health market. His presentation highlighted the vast potential of monoclonal antibodies (mABs) which serve as the basis of Nexvet’s PETisationTM technology in producing antibodies for dogs, cats and horses, in addition to highlighting their advantages over small molecule compounds.

“It was a great opportunity to present at this prestigious conference and to highlight the extensive and promising path ahead for monoclonal antibodies in animal health, and our PETisationTM technology. The presentation was very well received and reinforced that the global pharmaceutical leaders are closely watching our progress,” said Professor Gearing.

Nexvet Chief Executive Officer, Dr Mark Heffernan said the Company is taking considered steps in building its commercial profile, and participating in this international conference was an important milestone in this process.

“The Informa Life Sciences Conference is a best-in-class industry event for Veterinary Science, and we are pleased to showcase our technology on the world stage,” said Dr Heffernan.

“We are committed to providing safer and more effective treatment options for companion animals and we know the market is receptive to this. This was just one of many important networking initiatives on the calendar for this year.”

About Nexvet

Nexvet Biopharma is developing safe, more effective and specific medicines for companion animals, (cats, dogs and horses). The Nexvet portfolio focuses on inflammatory disease, pain and cancer. The portfolio is composed of drugs based on successful human biologics drugs in these indications, converted to species-specific versions by Nexvet’s proprietary PETization™ technology.

PETization™ converts biologics to species-specific analogues through a simple, rapid one-step process with a high success rate. For decades animal health companies have used drugs based on human health products with typically little optimization for the animal targets. Nexvet will address this shortcoming by introducing new highly optimized products in areas of greatest market need.

The area of biologics has become a massive growth area in human medicine, responsible for many of the most effective drugs on the market. Biologics are drugs based on natural proteins with typically good efficacy, high specificity and an excellent side-effect profile. To date, innovation and competition in biologics in the $20 billion global veterinary pharmaceuticals market has been limited. Nexvet’s team have international track records in developing human biologics combined with Veterinary expertise. Nexvet’s expertise in biologics R&D confers a strong competitive advantage and has generated an extensive intellectual property position, making Nexvet an attractive licensing partner and/or acquisition target.

Nexvet is based in Melbourne, Australia, with partners and investors located around the world. If you would like to know more about Nexvet, please visit the website at www.nexvet.com and via the contacts below.

Further information:

Investors

Mark Heffernan

Chief Executive Officer, Nexvet

+61 447 155 542

mark.heffernan@nexvet.com

Media

Haley Price

Buchan Consulting

+61 3 8866 4722

+61 423 139 163

hprice@buchanwe.com.au



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES